Anna Maria Buccoliero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Maria Buccoliero has a total of 284 co-authors. Here are the top co-authors by number of shared publications:
Gian Luigi Taddei
28 shared publicationsFrancesca Castiglione
Department of Biomedicine, Careggi Hospital, Florence, Italy
19 shared publications- Antonio Taddei
University of Florence
17 shared publications - Lorenzo Genitori
Ospedale Pediatrico Meyer
17 shared publications Flavio Giordano
Meyer Children’s Hospital IRCCS
14 shared publicationsFederico Mussa
Meyer Children’s Hospital IRCCS
13 shared publications
Latest Publications
- 12 October 2026
- Published by Wiley in Neuropathology
- Vol. 46 (5) , e70080
Pediatric Large Cell/Anaplastic Medulloblastomas: Diagnostic Concordance and Multi‐Classifier DNA Methylation Profiling, Including the In‐House MAGIBU Framework
Large cell/anaplastic medulloblastoma is a high‐risk variant whose histopathological diagnosis can be challenging. We analyzed 12 pediatric cases enriched for LC/A morphology, with centralized review available for 11. In this deliberately selected, diagnostically challenging series, institutional and central LC/A versus non‐LC/A assessments were discordant in 36% (4 of 11), illustrating the difficulty of applying the LC/A designation rather than a general estimate of inter‐observer reproducibility. DNA methylation profiling was performed using four classifiers: Heidelberg CNS Tumor Methylation Classifier, Methylscape Analysis, EpiDiP, and the MAGIBU classifier, which applies a UMAP‐based distance approach. Tumor classification was largely concordant across platforms, identifying two WNT ‐activated medulloblastomas, eight non‐ WNT /non‐ SHH medulloblastomas, and one tumor reclassified as an embryonal tumor with multilayered rosettes. One misclassification occurred with EpiDiP, where an SHH ‐activated medulloblastoma aligned with the normal cerebellar cortex reference profile. Copy number analysis revealed MYC amplification in two non‐ WNT /non‐ SHH tumors, chromosome 6 loss in both WNT ‐activated cases, and isochromosome 17q in one MYC ‐amplified non‐ WNT /non‐ SHH tumor. Adjunctive molecular data for a subset of cases were obtained from PedcBioPortal. The reclassified tumor lacked canonical molecular alterations but harbored additional CTNNB1 and TP53 variants whose contribution to its pathogenesis remains uncertain. One WNT ‐activated medulloblastoma also carried a CTNNB1 variant. The MAGIBU classifier correctly identified the ETMR case, classified all remaining tumors as medulloblastomas, and showed concordant subgroup assignment with the Heidelberg CNS Tumor Methylation Classifier and Methylscape Analysis, including the SHH ‐activated case misclassified by EpiDiP. On external validation across four independent medulloblastoma cohorts ( n = 1063), MAGIBU achieved 98.5% family‐level recall and 96.4% subclass‐level recall. In conclusion, our findings indicate that, in these diagnostically challenging, LC/A‐enriched cases, morphology‐based diagnostic assessment can be inconsistent. DNA methylation profiling serves to refine tumor reclassification and ensure accurate risk stratification. Interpreting each tumor across complementary classifiers provides a triangulation that enhances diagnostic robustness.
- 12 October 2026
- Published by Wiley in Neuropathology
- Vol. 46 (5) , e70080
Pediatric Large Cell/Anaplastic Medulloblastomas: Diagnostic Concordance and Multi‐Classifier DNA Methylation Profiling, Including the In‐House MAGIBU Framework
Large cell/anaplastic medulloblastoma is a high‐risk variant whose histopathological diagnosis can be challenging. We analyzed 12 pediatric cases enriched for LC/A morphology, with centralized review available for 11. In this deliberately selected, diagnostically challenging series, institutional and central LC/A versus non‐LC/A assessments were discordant in 36% (4 of 11), illustrating the difficulty of applying the LC/A designation rather than a general estimate of inter‐observer reproducibility. DNA methylation profiling was performed using four classifiers: Heidelberg CNS Tumor Methylation Classifier, Methylscape Analysis, EpiDiP, and the MAGIBU classifier, which applies a UMAP‐based distance approach. Tumor classification was largely concordant across platforms, identifying two WNT ‐activated medulloblastomas, eight non‐ WNT /non‐ SHH medulloblastomas, and one tumor reclassified as an embryonal tumor with multilayered rosettes. One misclassification occurred with EpiDiP, where an SHH ‐activated medulloblastoma aligned with the normal cerebellar cortex reference profile. Copy number analysis revealed MYC amplification in two non‐ WNT /non‐ SHH tumors, chromosome 6 loss in both WNT ‐activated cases, and isochromosome 17q in one MYC ‐amplified non‐ WNT /non‐ SHH tumor. Adjunctive molecular data for a subset of cases were obtained from PedcBioPortal. The reclassified tumor lacked canonical molecular alterations but harbored additional CTNNB1 and TP53 variants whose contribution to its pathogenesis remains uncertain. One WNT ‐activated medulloblastoma also carried a CTNNB1 variant. The MAGIBU classifier correctly identified the ETMR case, classified all remaining tumors as medulloblastomas, and showed concordant subgroup assignment with the Heidelberg CNS Tumor Methylation Classifier and Methylscape Analysis, including the SHH ‐activated case misclassified by EpiDiP. On external validation across four independent medulloblastoma cohorts ( n = 1063), MAGIBU achieved 98.5% family‐level recall and 96.4% subclass‐level recall. In conclusion, our findings indicate that, in these diagnostically challenging, LC/A‐enriched cases, morphology‐based diagnostic assessment can be inconsistent. DNA methylation profiling serves to refine tumor reclassification and ensure accurate risk stratification. Interpreting each tumor across complementary classifiers provides a triangulation that enhances diagnostic robustness.
- Open Access
- 1 October 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (5) , e200416
Associations of Cortical and Subcortical White Matter Morphometric Abnormalities With Clinical and Genetic Findings in STXBP1 Encephalopathy
Background and ObjectivesDisease-causing variants in the syntaxin-binding protein 1 (STXBP1) gene are among the most common genetic causes of developmental and epileptic encephalopathies and are as...
- 1 October 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (5) , e200416
Open AccessAssociations of Cortical and Subcortical White Matter Morphometric Abnormalities With Clinical and Genetic Findings in STXBP1 Encephalopathy
Background and ObjectivesDisease-causing variants in the syntaxin-binding protein 1 (STXBP1) gene are among the most common genetic causes of developmental and epileptic encephalopathies and are as...
- Open Access
- 6 July 2026
- Published by Springer Nature in Neuroradiology
- Vol. 68 (8) , 1-16
Enhanced detection of subtle cortical abnormalities in focal epilepsy using 7 T MRI surface-based models and graph neural networks
Purpose: MRI detection of subtle focal cortical dysplasia (FCD)-like abnormalities remains challenging in focal epilepsy. Higher signal-to-noise ratio and spatial resolution offered by ultra-high-field 7T MRI and surface-based graph-neural-network (GNN) analysis may improve detection of subtle cortical abnormalities. We evaluated whether combining 7T MRI with a surface-based GNN classifier improves lesion detection in focal epilepsy of suspected structural origin. Methods: We analyzed paired 7T and 3T MRI datasets from 87 patients with focal epilepsy (78.1% pediatric) and 10 internal healthy control individuals. We processed T1-weighted and Fluid-Attenuated-Inversion-Recovery MRI using a surface-based framework and a pre-trained GNN classifier developed within the Multi-centre-Epilepsy-Lesion-Detection project. We compared classifier outputs with expert visual MRI assessment, clinical and surface electroencephalography (EEG) localization (all patients), stereo-EEG (ten patients) and histopathological (17 patients) findings. We evaluated diagnostic yield and lesion conspicuity, and performed within-subject comparisons between 7T and 3T. Results: Following quality controls, we included 70 patients. The 7T MRI-based classifier identified lesion clusters concordant with visual 3T MRI and electroclinical localization in 25/37 (67.6%) MRI-positive patients, electroclinical-concordant clusters in 15/33 (45.4%) 3T MRI-negatives, stereo-EEG-concordant clusters in 7/10 (70.0%) patients and surgically-concordant clusters in 11/17 (64.7%). Among classifier-positive patients (40/70, 57.1%), 7T allowed detection of previously hidden lesions in 15/40 (37.5%) patients, and improved detection of known lesions in 11/40 (27.5%). Conclusion: Combining 7T MRI with surface-based GNN analysis improves detection and characterization of FCD-like abnormalities in focal epilepsy, particularly in patients with unrevealing 3T MRI, supporting the adoption of advanced neuroimaging in presurgical epilepsy assessment.
- 6 July 2026
- Published by Springer Nature in Neuroradiology
- Vol. 68 (8) , 1-16
Open AccessEnhanced detection of subtle cortical abnormalities in focal epilepsy using 7 T MRI surface-based models and graph neural networks
Purpose: MRI detection of subtle focal cortical dysplasia (FCD)-like abnormalities remains challenging in focal epilepsy. Higher signal-to-noise ratio and spatial resolution offered by ultra-high-field 7T MRI and surface-based graph-neural-network (GNN) analysis may improve detection of subtle cortical abnormalities. We evaluated whether combining 7T MRI with a surface-based GNN classifier improves lesion detection in focal epilepsy of suspected structural origin. Methods: We analyzed paired 7T and 3T MRI datasets from 87 patients with focal epilepsy (78.1% pediatric) and 10 internal healthy control individuals. We processed T1-weighted and Fluid-Attenuated-Inversion-Recovery MRI using a surface-based framework and a pre-trained GNN classifier developed within the Multi-centre-Epilepsy-Lesion-Detection project. We compared classifier outputs with expert visual MRI assessment, clinical and surface electroencephalography (EEG) localization (all patients), stereo-EEG (ten patients) and histopathological (17 patients) findings. We evaluated diagnostic yield and lesion conspicuity, and performed within-subject comparisons between 7T and 3T. Results: Following quality controls, we included 70 patients. The 7T MRI-based classifier identified lesion clusters concordant with visual 3T MRI and electroclinical localization in 25/37 (67.6%) MRI-positive patients, electroclinical-concordant clusters in 15/33 (45.4%) 3T MRI-negatives, stereo-EEG-concordant clusters in 7/10 (70.0%) patients and surgically-concordant clusters in 11/17 (64.7%). Among classifier-positive patients (40/70, 57.1%), 7T allowed detection of previously hidden lesions in 15/40 (37.5%) patients, and improved detection of known lesions in 11/40 (27.5%). Conclusion: Combining 7T MRI with surface-based GNN analysis improves detection and characterization of FCD-like abnormalities in focal epilepsy, particularly in patients with unrevealing 3T MRI, supporting the adoption of advanced neuroimaging in presurgical epilepsy assessment.
- Open Access
- 9 January 2026
- Published by Springer Nature in Research Square
High-sensitivity Approach for Detection of Tert Promoter Variants in Shh-activated Pediatric Medulloblastomas
TERT promoter ( TERT p) hotspot variants − 124C > T (C228T) and − 146C > T (C250T) are recurrent in various central nervous system tumors and serve as established prognostic markers in many cases. Among medulloblastoma molecular subgroups, TERT p variants are most frequently observed in adult SHH-activated (Sonic Hedgehog) medulloblastomas and are traditionally considered mutually exclusive one another. However, their prognostic significance remains unclear and appears to be subgroup-dependent, being associated with improved survival in SHH-activated tumors but poorer outcomes in Group 4 medulloblastomas. We investigated the presence of the C228T and C250T hotspot variants in TERT p using high-sensitivity droplet digital PCR (ddPCR) in ten consecutive pediatric SHH-activated medulloblastomas (nine desmoplastic/nodular and one extensively nodular) with sufficient residual material available for analysis. Both variants were detected in all tumors, with variant allele frequencies (VAFs) ranging from 0.14% to 61.7% for C228T and 0.06% to 44.6% for C250T. Notably, only the two patients aged ≥ 10 years exhibited high VAFs. Additionally, we compared the results of 5 out of our 10 cases, which were also analyzed by Children’s Brain Tumor Network (CBTN; PedcBioPortal) through Whole Genome Sequencing (WGS). In all five cases, the CBTN analyses yielded negative results. In conclusion, our findings indicate that the two TERT p variants may co-occur; they are ubiquitously present at low VAFs in younger children, while higher TERT p variants VAFs increase with patient age. Larger cohorts are required to validate these findings and to elucidate the prognostic significance of TERT p variants at low and high VAFs in SHH-activated medulloblastomas.
- 9 January 2026
- Published by Springer Nature in Research Square
Open AccessHigh-sensitivity Approach for Detection of Tert Promoter Variants in Shh-activated Pediatric Medulloblastomas
TERT promoter ( TERT p) hotspot variants − 124C > T (C228T) and − 146C > T (C250T) are recurrent in various central nervous system tumors and serve as established prognostic markers in many cases. Among medulloblastoma molecular subgroups, TERT p variants are most frequently observed in adult SHH-activated (Sonic Hedgehog) medulloblastomas and are traditionally considered mutually exclusive one another. However, their prognostic significance remains unclear and appears to be subgroup-dependent, being associated with improved survival in SHH-activated tumors but poorer outcomes in Group 4 medulloblastomas. We investigated the presence of the C228T and C250T hotspot variants in TERT p using high-sensitivity droplet digital PCR (ddPCR) in ten consecutive pediatric SHH-activated medulloblastomas (nine desmoplastic/nodular and one extensively nodular) with sufficient residual material available for analysis. Both variants were detected in all tumors, with variant allele frequencies (VAFs) ranging from 0.14% to 61.7% for C228T and 0.06% to 44.6% for C250T. Notably, only the two patients aged ≥ 10 years exhibited high VAFs. Additionally, we compared the results of 5 out of our 10 cases, which were also analyzed by Children’s Brain Tumor Network (CBTN; PedcBioPortal) through Whole Genome Sequencing (WGS). In all five cases, the CBTN analyses yielded negative results. In conclusion, our findings indicate that the two TERT p variants may co-occur; they are ubiquitously present at low VAFs in younger children, while higher TERT p variants VAFs increase with patient age. Larger cohorts are required to validate these findings and to elucidate the prognostic significance of TERT p variants at low and high VAFs in SHH-activated medulloblastomas.
- Open Access
- 22 December 2025
- Published by MDPI AG in Hematology Reports
- Vol. 18 (1) , 2
Durable Response in Histiocytic Sarcoma After Allogeneic Stem Cell Transplantation: A Case Report
Background and Clinical Significance: Histiocytic sarcoma (HS) is a rare and aggressive form of malignant histiocytosis, often associated with poor prognosis. The diagnosis and management of HS are challenging due to the complexity of its pathogenesis, molecular profile, and the unclear cellular origin of histiocytic neoplasms, compounded by the limited literature on treatment strategies. Case Presentation: We report the case of a young patient with HS localized to the lymph nodes, spleen, and liver, who also presented with hemophagocytic lymphohistiocytosis (HLH) documented on bone marrow biopsy. Initial treatment with CHOEP-21 and ICE-21 chemotherapy resulted in only a partial metabolic response, as evidenced by a Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET)/CT scan. Given the aggressive nature of the disease and the presence of HLH, an allogeneic hematopoietic stem cell transplantation (HSCT) from a matched unrelated donor was performed as consolidation therapy, leading to a progressive complete response without significant toxicity. A suspected relapse at 18 months post-transplant was excluded following a mediastinal lymph node biopsy, which revealed a benign intravascular papillary endothelial hyperplasia (IPEH). Over five years post-diagnosis and more than four years after transplantation, the patient remains in complete remission with full functional recovery. Conclusions: This case highlights the diagnostic and molecular challenges of HS and demonstrates the curative potential of early allogeneic HSCT, even when only partial remission is initially achieved.
- 22 December 2025
- Published by MDPI AG in Hematology Reports
- Vol. 18 (1) , 2
Open AccessDurable Response in Histiocytic Sarcoma After Allogeneic Stem Cell Transplantation: A Case Report
Background and Clinical Significance: Histiocytic sarcoma (HS) is a rare and aggressive form of malignant histiocytosis, often associated with poor prognosis. The diagnosis and management of HS are challenging due to the complexity of its pathogenesis, molecular profile, and the unclear cellular origin of histiocytic neoplasms, compounded by the limited literature on treatment strategies. Case Presentation: We report the case of a young patient with HS localized to the lymph nodes, spleen, and liver, who also presented with hemophagocytic lymphohistiocytosis (HLH) documented on bone marrow biopsy. Initial treatment with CHOEP-21 and ICE-21 chemotherapy resulted in only a partial metabolic response, as evidenced by a Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET)/CT scan. Given the aggressive nature of the disease and the presence of HLH, an allogeneic hematopoietic stem cell transplantation (HSCT) from a matched unrelated donor was performed as consolidation therapy, leading to a progressive complete response without significant toxicity. A suspected relapse at 18 months post-transplant was excluded following a mediastinal lymph node biopsy, which revealed a benign intravascular papillary endothelial hyperplasia (IPEH). Over five years post-diagnosis and more than four years after transplantation, the patient remains in complete remission with full functional recovery. Conclusions: This case highlights the diagnostic and molecular challenges of HS and demonstrates the curative potential of early allogeneic HSCT, even when only partial remission is initially achieved.
- Open Access
- 1 December 2025
- Published by Siapec Servizi Srl in Pathologica
- Vol. 117 (6) , 610-617
Marked hepatic fibrosis with progression towards cirrhosis in generalized arterial calcification of infancy: an unreported association observed in a case carryng a novel ENPP1 variant
Generalized arterial calcification of infancy (GACI) is a rare autosomal recessive disorder characterized by dysregulated calcium-phosphate metabolism, leading to mineral deposition within the internal elastic lamina of medium- and large-sized arteries. This results in arterial wall thickening and luminal narrowing due to intimal hyperplasia, causing significant vascular disruption. Approximately 70% of cases (GACI type 1) are caused by biallelic loss-of-function mutations in the ENPP1 gene, with nearly 40 pathogenic variants reported. We report a case of an infant diagnosed with GACI type 1 who died at 7 weeks of age. The patient was delivered via cesarean section at 36 weeks of gestation after a pregnancy complicated by polyhydramnios. The parents were second-degree cousins, with a history of two neonatal deaths of unknown etiology and one miscarriage. Autopsy revealed diffuse arterial calcification with prominent involvement of the coronary arteries. Notably, the liver showed fibrosis progressing to cirrhosis. Genetic analysis through trio exome sequencing identified a novel homozygous nonsense variant in ENPP1 (c.553C > T; p.Gln185Ter), inherited from both parents. This stop-gain variant is predicted to produce a severely truncated, non-functional or absent protein. This case is notable for two key aspects: a previously unreported association between GACI and progressive hepatic fibrosis evolving into cirrhosis, and the identification of a novel pathogenic ENPP1 variant not previously described in the literature.
- 1 December 2025
- Published by Siapec Servizi Srl in Pathologica
- Vol. 117 (6) , 610-617
Open AccessMarked hepatic fibrosis with progression towards cirrhosis in generalized arterial calcification of infancy: an unreported association observed in a case carryng a novel ENPP1 variant
Generalized arterial calcification of infancy (GACI) is a rare autosomal recessive disorder characterized by dysregulated calcium-phosphate metabolism, leading to mineral deposition within the internal elastic lamina of medium- and large-sized arteries. This results in arterial wall thickening and luminal narrowing due to intimal hyperplasia, causing significant vascular disruption. Approximately 70% of cases (GACI type 1) are caused by biallelic loss-of-function mutations in the ENPP1 gene, with nearly 40 pathogenic variants reported. We report a case of an infant diagnosed with GACI type 1 who died at 7 weeks of age. The patient was delivered via cesarean section at 36 weeks of gestation after a pregnancy complicated by polyhydramnios. The parents were second-degree cousins, with a history of two neonatal deaths of unknown etiology and one miscarriage. Autopsy revealed diffuse arterial calcification with prominent involvement of the coronary arteries. Notably, the liver showed fibrosis progressing to cirrhosis. Genetic analysis through trio exome sequencing identified a novel homozygous nonsense variant in ENPP1 (c.553C > T; p.Gln185Ter), inherited from both parents. This stop-gain variant is predicted to produce a severely truncated, non-functional or absent protein. This case is notable for two key aspects: a previously unreported association between GACI and progressive hepatic fibrosis evolving into cirrhosis, and the identification of a novel pathogenic ENPP1 variant not previously described in the literature.
- Open Access
- 1 October 2025
- Published by Siapec Servizi Srl in Pathologica
- Vol. 117 (5) , 475-485
The contribution of methylation profiling in neuropathological diagnosis of central nervous system tumors in children, adolescent and young adults
Methylation of CpG islands plays a crucial role in the regulation of gene expression. The study of DNA methylation profiles offers deep insights into key oncogenic processes and facilitates the differentiation of tumor entities at the epigenetic level. Methylation profiling was performed on 8 CNS tumors (6 children, 1 adolescent, 1 young adult) with inconclusive diagnoses, available frozen tissue, and surgeries dating back over 5 years. Our goal was to correlate the resulting methylation classes with the clinical-radiological data and to evaluate the diagnostic and prognostic power of this analysis. The resulting molecularly defined diagnoses were: pilocytic astrocytoma (3 cases), pilocytic astrocytoma subclass FGFR1 altered (1 case), ganglioglioma (2 cases), diffuse leptomeningeal glioneuronal tumor subtype 1 (1 case), and diffuse midline glioma H3.3K27-altered, subtype H3K27 mutant or EZHIP-expressing (1 case). Clinico-pathological features of each tumor in our series are discussed. The clinical behavior was consistent with the molecular diagnosis in all cases but one that was lost to follow-up. In our series, the initial diagnostic failure in 3 of the 8 cases was due to the fact that the pathological entities-diffuse midline glioma, H3 K27-altered, pilocytic astrocytoma with FGFR1 alteration and diffuse leptomeningeal glioneuronal tumor -had not yet been fully characterized or widely recognized in the literature at the time of diagnosis. In the remaining cases, the lack of distinctive histopathological features hindered a definitive diagnosis. In conclusion, according to our experience, DNA methylation profile analysis represents a very attractive diagnostic tool and provides important support for the diagnosis and classification of CNS tumors.
- 1 October 2025
- Published by Siapec Servizi Srl in Pathologica
- Vol. 117 (5) , 475-485
Open AccessThe contribution of methylation profiling in neuropathological diagnosis of central nervous system tumors in children, adolescent and young adults
Methylation of CpG islands plays a crucial role in the regulation of gene expression. The study of DNA methylation profiles offers deep insights into key oncogenic processes and facilitates the differentiation of tumor entities at the epigenetic level. Methylation profiling was performed on 8 CNS tumors (6 children, 1 adolescent, 1 young adult) with inconclusive diagnoses, available frozen tissue, and surgeries dating back over 5 years. Our goal was to correlate the resulting methylation classes with the clinical-radiological data and to evaluate the diagnostic and prognostic power of this analysis. The resulting molecularly defined diagnoses were: pilocytic astrocytoma (3 cases), pilocytic astrocytoma subclass FGFR1 altered (1 case), ganglioglioma (2 cases), diffuse leptomeningeal glioneuronal tumor subtype 1 (1 case), and diffuse midline glioma H3.3K27-altered, subtype H3K27 mutant or EZHIP-expressing (1 case). Clinico-pathological features of each tumor in our series are discussed. The clinical behavior was consistent with the molecular diagnosis in all cases but one that was lost to follow-up. In our series, the initial diagnostic failure in 3 of the 8 cases was due to the fact that the pathological entities-diffuse midline glioma, H3 K27-altered, pilocytic astrocytoma with FGFR1 alteration and diffuse leptomeningeal glioneuronal tumor -had not yet been fully characterized or widely recognized in the literature at the time of diagnosis. In the remaining cases, the lack of distinctive histopathological features hindered a definitive diagnosis. In conclusion, according to our experience, DNA methylation profile analysis represents a very attractive diagnostic tool and provides important support for the diagnosis and classification of CNS tumors.
- Open Access
Safety and efficacy of frontline doxorubicin in combination with temozolomide and valproic acid for the treatment of pediatric malignant gliomas: results of a phase 2 study
Background: Despite innovative approaches, outcomes for pediatric high-grade gliomas (HGGs) remain poor. Doxorubicin (Dox) is commonly used to treat many childhood cancers, with a well-known safety profile, although the blood-brain barrier limits its use in central nervous system tumors. However, its antineoplastic activity is reported in vitro and in vivo glioma models. We aimed to assess safety and activity of the addition of Dox to the standard treatment in this population. Methods: A monocentric, non-randomized, phase II interventional study was opened at Meyer Children’s Hospital IRCCS in Florence (EudraCT 2015-002307-28), introducing Dox 100 mg/m 2 over a 96-hour infusion following chemo-radiotherapy as a post-operative treatment, alongside valproic acid throughout the treatment. The endpoints were safety and efficacy of the add-on Dox approach in prolonged infusion. Results: Twenty-one heterogeneous malignant pediatric HGGs patients were enrolled. However at the time of Dox administration, only twelve patients presented a performance status sufficient to receive the investigational drug. Dox single course-group (10 patients) exhibited a median overall survival (OS) of 13.7 months (6.9 months in non-Dox-treated patients). Analyzing a multivariate Cox regression, patients with diffuse midline glioma showed a significantly higher risk of events compared to those with other HGG (approximately 80%, p = 0.008). Dox-treated DMG shows a slight reduction in event rate (9.52 vs 12.55). Interestingly, all patients (6/12) with hemispheric malignant glioma, who had undergone Dox, relapsed at sites distant from the primary tumor. Currently, only one patient is alive (a Dox-treated grade 3 anaplastic pleomorphic xanthoastrocytoma), Considering the Dox-treated patients, despite 35 Serious Adverse Reactions related to Dox were reported, predominantly hematologic, the treatment after focal radiotherapy was well tolerated. No signs of cardiotoxicity, nephrotoxicity, or neurotoxicity following Dox infusion were reported. Conclusion: This preliminary study shows that a prolonged infusion Dox add-on to standard multimodal treatment for pediatric HGGs is well tolerated with no significant adverse events and with a positive impact in terms of survival, although not statistically significant.
Open AccessSafety and efficacy of frontline doxorubicin in combination with temozolomide and valproic acid for the treatment of pediatric malignant gliomas: results of a phase 2 study
Background: Despite innovative approaches, outcomes for pediatric high-grade gliomas (HGGs) remain poor. Doxorubicin (Dox) is commonly used to treat many childhood cancers, with a well-known safety profile, although the blood-brain barrier limits its use in central nervous system tumors. However, its antineoplastic activity is reported in vitro and in vivo glioma models. We aimed to assess safety and activity of the addition of Dox to the standard treatment in this population. Methods: A monocentric, non-randomized, phase II interventional study was opened at Meyer Children’s Hospital IRCCS in Florence (EudraCT 2015-002307-28), introducing Dox 100 mg/m 2 over a 96-hour infusion following chemo-radiotherapy as a post-operative treatment, alongside valproic acid throughout the treatment. The endpoints were safety and efficacy of the add-on Dox approach in prolonged infusion. Results: Twenty-one heterogeneous malignant pediatric HGGs patients were enrolled. However at the time of Dox administration, only twelve patients presented a performance status sufficient to receive the investigational drug. Dox single course-group (10 patients) exhibited a median overall survival (OS) of 13.7 months (6.9 months in non-Dox-treated patients). Analyzing a multivariate Cox regression, patients with diffuse midline glioma showed a significantly higher risk of events compared to those with other HGG (approximately 80%, p = 0.008). Dox-treated DMG shows a slight reduction in event rate (9.52 vs 12.55). Interestingly, all patients (6/12) with hemispheric malignant glioma, who had undergone Dox, relapsed at sites distant from the primary tumor. Currently, only one patient is alive (a Dox-treated grade 3 anaplastic pleomorphic xanthoastrocytoma), Considering the Dox-treated patients, despite 35 Serious Adverse Reactions related to Dox were reported, predominantly hematologic, the treatment after focal radiotherapy was well tolerated. No signs of cardiotoxicity, nephrotoxicity, or neurotoxicity following Dox infusion were reported. Conclusion: This preliminary study shows that a prolonged infusion Dox add-on to standard multimodal treatment for pediatric HGGs is well tolerated with no significant adverse events and with a positive impact in terms of survival, although not statistically significant.
- 23 March 2025
- Published by Elsevier in Human Pathology
- Vol. 157, 105763
Histologic alterations are common in Monogenic Disease patients with ‘healthy’ endoscopy: Results from a GIPAD-GIPPI multicenter study
- 23 March 2025
- Published by Elsevier in Human Pathology
- Vol. 157, 105763
Histologic alterations are common in Monogenic Disease patients with ‘healthy’ endoscopy: Results from a GIPAD-GIPPI multicenter study
- 20 November 2023
- Published by Elsevier in Epilepsy Research
- Vol. 199, 107258
Leat-associated seizures the possible role of EAAT2, pyruvate carboxylase and glutamine synthetase
- 20 November 2023
- Published by Elsevier in Epilepsy Research
- Vol. 199, 107258
Leat-associated seizures the possible role of EAAT2, pyruvate carboxylase and glutamine synthetase